{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:35Z","timestamp":1793214635162,"version":"4.5.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Effective nonsteroidal therapies are needed for uveitic macular edema (UME).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the safety, tolerability, and effects associated with intravitreal (IVT) vamikibart in UME.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This multipart, multicenter, open-label, multiple-ascending-dose nonrandomized clinical trial of vamikibart (RO7200220), a novel IVT anti\u2013interleukin 6 monoclonal antibody, included monotherapy in participants with UME secondary to noninfectious uveitis (NIU). DOVETAIL was conducted from July 2019 to November 2023 at 18 sites in the US. Adults with UME secondary to NIU (optical coherence tomography central subfield thickness [CST] \u2265325 \u00b5m) were eligible for inclusion. Data were analyzed from February 2024 to May 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Participants were enrolled into 3 dose groups (0.25, 1, or 2.5 mg) and received IVT vamikibart at day 1, week 4, and week 8, followed by observation not receiving treatment until weeks 20 (2.5 mg) or 36 (0.25 or 1 mg).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcomes were safety and tolerability; exploratory outcomes included best-corrected visual acuity (BCVA) and CST.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this nonrandomized study, vamikibart was associated with improvements in BCVA and CST across all doses. A total of 37 participants with UME were enrolled (0.25 mg: n\u2009=\u200912; 1 mg: n\u2009=\u200912; 2.5 mg: n\u2009=\u200913); 22 of 37 patients (59.5%) were female, and the mean (SD) age was 63.5 (15.4) years. At week 12, mean (SD) change from baseline in BCVA letter score was +9.9 (8.9), an approximate 2-line improvement (improvements in letter scores of +11.1 [8.1], +10.3 [8.0], and +8.4 [10.8] for the 0.25-mg, 1-mg, and 2.5-mg groups, respectively), and mean (SD) CST reduction was \u2212165.1 (147.5) \u00b5m (\u2212125.0 [135.0] \u00b5m, \u2212188.1 [152.4] \u00b5m, and \u2212183.6 [159.4] \u00b5m for the 3 dose groups, respectively). Of 37 participants, 36 continued vamikibart throughout the 12 weeks. Ocular adverse events (AEs) in the study eye were reported in 19 participants (51.4%), including 1 serious AE (uveitis worsening, unrelated to study drug) and 1 treatment-related AE (VA reduced transiently). No cases of retinal vasculitis (occlusive or nonocclusive) were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>\n                      These results from the phase 1 DOVETAIL nonrandomized clinical trial provide preliminary evidence supporting safety, tolerability, and potential effects of vamikibart for UME secondary to NIU. Two phase 3 clinical trials (MEERKAT [\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05642312?cond=NCT05642312&amp;amp;amp;rank=1\">NCT05642312<\/jats:ext-link>\n                      ] and SANDCAT [\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05642325?cond=NCT05642325&amp;amp;amp;rank=1\">NCT05642325<\/jats:ext-link>\n                      ]) are underway to further evaluate vamikibart in UME.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT06771271?cond=NCT06771271&amp;amp;amp;rank=1\">NCT06771271<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2026.0610","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:00:37Z","timestamp":1775746837000},"page":"442","source":"Crossref","is-referenced-by-count":11,"title":["Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema"],"prefix":"10.1001","volume":"144","author":[{"given":"Sumit","family":"Sharma","sequence":"first","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe","family":"Lin","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Hu","sequence":"additional","affiliation":[{"name":"Cumberland Valley Retina PC, Hagerstown, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric B.","family":"Suhler","sequence":"additional","affiliation":[{"name":"Casey Eye Institute and VA Portland Health Care System, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Pauly-Evers","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Holmes","sequence":"additional","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Barekati","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Willen","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lachlan","family":"Macgregor","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Steeples","sequence":"additional","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenka","family":"Haskova","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Feenstra","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Silverman","sequence":"additional","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Passemard","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Fauser","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Mesquida","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Basel, Switzerland"},{"name":"F. Hoffmann-La Roche AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"eoi260015r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjo.78.1.1","article-title":"The treatment of chronic uveitic macular oedema.","volume":"78","author":"Dick","year":"1994","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"eoi260015r2","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.ophtha.2006.03.027","article-title":"Impact of macular edema on visual acuity in uveitis.","volume":"113","author":"Lardenoye","year":"2006","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi260015r3","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ophtha.2013.09.023","article-title":"Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema.","volume":"121","author":"Levin","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"eoi260015r4","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1016\/j.ophtha.2014.07.007","article-title":"Long-term clinical outcome and causes of vision loss in patients with uveitis.","volume":"121","author":"Tomkins-Netzer","year":"2014","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi260015r5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ophtha.2020.08.035","article-title":"Seven-year outcomes of uveitic macular edema: the Multicenter Uveitis Steroid Treatment trial and follow-up study results.","volume":"128","author":"Tomkins-Netzer","year":"2021","journal-title":"Ophthalmology"},{"issue":"9","key":"eoi260015r6","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2023.04.011","article-title":"Intravitreal therapy for uveitic macular edema-ranibizumab versus methotrexate versus the dexamethasone implant: the MERIT trial results.","volume":"130","author":"Acharya","year":"2023","journal-title":"Ophthalmology"},{"issue":"12","key":"eoi260015r7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1080\/14740338.2019.1692810","article-title":"Safety of systemic therapy for noninfectious uveitis.","volume":"18","author":"Ormaechea","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"eoi260015r8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2147\/DDDT.S166092","article-title":"Update in treatment of uveitic macular edema.","volume":"13","author":"Koronis","year":"2019","journal-title":"Drug Des Dev Ther"},{"key":"eoi260015r9","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.5301\/EJO.2010.6056","article-title":"The role of steroids in the management of uveitic macular edema.","volume":"21","author":"de Smet","year":"2011","journal-title":"Eur J Ophthalmol"},{"issue":"18","key":"eoi260015r11","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.3390\/jcm10184133","article-title":"Update on the management of uveitic macular edema.","volume":"10","author":"Teper","year":"2021","journal-title":"J Clin Med"},{"issue":"12","key":"eoi260015r12","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1001\/jamaophthalmol.2019.3964","article-title":"Antimetabolite therapy for uveitis: methotrexate or mycophenolate?","volume":"137","author":"Jabs","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"eoi260015r13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4103\/0301-4738.58472","article-title":"Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance.","volume":"58","author":"Mathews","year":"2010","journal-title":"Indian J Ophthalmol"},{"issue":"6","key":"eoi260015r14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ophtha.2022.02.002","article-title":"Outcomes of uveitic macular edema in the First-line Antimetabolites as Steroid-Sparing Treatment Uveitis Trial.","volume":"129","author":"Tsui","year":"2022","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi260015r16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. results of the first international workshop.","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"eoi260015r17","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.autrev.2017.08.002","article-title":"Targeting interleukin-6 in autoimmune uveitis.","volume":"16","author":"Mesquida","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"5","key":"eoi260015r18","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.3390\/ijms24054676","article-title":"Interleukin-6 and macular edema: a review of outcomes with inhibition.","volume":"24","author":"Yang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"eoi260015r19","first-page":"917","article-title":"Aqueous humor interleukin-6 levels in uveitis.","volume":"31","author":"Murray","year":"1990","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"eoi260015r20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/092739490500282","article-title":"Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies.","volume":"12","author":"Perez","year":"2004","journal-title":"Ocul Immunol Inflamm"},{"key":"eoi260015r21","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fimmu.2020.00358","article-title":"Cytokine profiling in aqueous humor samples from patients with non-infectious uveitis associated with systemic inflammatory diseases.","volume":"11","author":"Bonacini","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"eoi260015r22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1167\/tvst.8.5.32","article-title":"Modelling macular edema: the effect of IL-6 and IL-6R blockade on human blood-retinal barrier integrity in vitro.","volume":"8","author":"Mesquida","year":"2019","journal-title":"Transl Vis Sci Technol"},{"issue":"3","key":"eoi260015r23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/cei.12295","article-title":"Interleukin-6 blockade in ocular inflammatory diseases.","volume":"176","author":"Mesquida","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"eoi260015r24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.exer.2018.09.009","article-title":"Inhibition of interleukin-6 trans-signaling prevents inflammation and endothelial barrier disruption in retinal endothelial cells.","volume":"178","author":"Valle","year":"2019","journal-title":"Exp Eye Res"},{"issue":"12","key":"eoi260015r25","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1016\/j.ophtha.2014.06.050","article-title":"Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema.","volume":"121","author":"Mesquida","year":"2014","journal-title":"Ophthalmology"},{"issue":"7","key":"eoi260015r26","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s10067-017-3672-z","article-title":"IL-6 blockade in the management of non-infectious uveitis.","volume":"36","author":"Lopalco","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"3","key":"eoi260015r27","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ophtha.2018.09.044","article-title":"Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN study.","volume":"126","author":"Heissigerov\u00e1","year":"2019","journal-title":"Ophthalmology"},{"key":"eoi260015r28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","article-title":"Primary (month-6) outcomes of the STOP-Uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis.","volume":"183","author":"Sepah","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"eoi260015r29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ophtha.2024.10.010","article-title":"Efficacy of subcutaneous and intravenous tocilizumab in noninfectious uveitis.","volume":"132","author":"Kherani","year":"2025","journal-title":"Ophthalmology"},{"issue":"8","key":"eoi260015r30","first-page":"5189","article-title":"A novel anti-IL-6 monoclonal antibody leads to restoration of IL-6-mediated endothelial barrier breakdown.","volume":"64","author":"Feenstra","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"eoi260015r31","first-page":"5100","article-title":"A novel intravitreal anti-IL-6 monoclonal antibody for uveitic macular edema (UME): preliminary results from the phase 1 DOVETAIL study.","volume":"64","author":"Sharma","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"eoi260015r32","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ophtha.2022.12.008","article-title":"Comparison of Snellen visual acuity measurements in retinal clinical practice to electronic ETDRS protocol visual acuity assessment.","volume":"130","author":"Baker","year":"2023","journal-title":"Ophthalmology"},{"key":"eoi260015r33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cyto.2017.02.023","article-title":"Intravitreal injection of anti-interleukin (IL)-6 antibody attenuates experimental autoimmune uveitis in mice.","volume":"96","author":"Tode","year":"2017","journal-title":"Cytokine"},{"issue":"1","key":"eoi260015r34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12348-019-0182-y","article-title":"Interleukin-6 inhibition in the management of non-infectious uveitis and beyond.","volume":"9","author":"Karkhur","year":"2019","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"5","key":"eoi260015r35","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ophtha.2021.11.013","article-title":"Anti-tumor necrosis factor a versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French Uveitis Network.","volume":"129","author":"Leclercq","year":"2022","journal-title":"Ophthalmology"},{"issue":"7","key":"eoi260015r36","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1097\/IAE.0000000000001690","article-title":"Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema.","volume":"38","author":"Mesquida","year":"2018","journal-title":"Retina"},{"key":"eoi260015r37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ajo.2018.12.019","article-title":"Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients.","volume":"200","author":"Vegas-Revenga","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"eoi260015r10","unstructured":"Pinto Proen\u00e7a? R, Dutra-Medeiros? M, O'Keefe? GD, . Treatment of uveitis. EyeWiki. Accessed May 1, 2025. https:\/\/eyewiki.org\/Treatment_of_Uveitis"},{"key":"eoi260015r15","unstructured":"HUMIRA (adalimumab). Prescribing information. AbbVie; 2023. Accessed March 5, 2026. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125057s424lbl.pdf#page=59"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2847244\/jamaophthalmology_sharma_2026_oi_260015_1778698664.50313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:00:48Z","timestamp":1779375648000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2847244"}},"subtitle":["The Phase 1 DOVETAIL Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2026.0610","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}